-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hong Kong September 30, 2021/PRNewswire/ - A few days ago, Kunbo Medical (2216.
HK), a global leader in precision interventional diagnosis and treatment of lung diseases, completed its lung targeted denervation radiofrequency ablation energy system (below Targeted Lung Denervation) The first clinical application of "TLD") has brought good news to the majority of patients with chronic obstructive pulmonary disease (COPD)
.
The operation was performed by the team of Professor Luo Fengming, Professor Liu Dan, Associate Professor Shen Yongchun, and Dr.
Zhu Hui from the Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University.
The whole procedure took less than 15 minutes and was discharged on the third day after the operation.
During the clinical follow-up, the patient expressed exercise The tolerance has improved significantly compared with the previous one
.
Chronic Obstructive Pulmonary Disease (COPD) is a common chronic respiratory disease and ranks the third cause of death in the world
.
According to the Frost & Sullivan report, in 2020, the number of patients with chronic obstructive pulmonary disease worldwide will reach 219.
Lung targeted denervation radiofrequency ablation for the treatment of COPD is an internationally leading emerging technology.
It is mainly used to achieve denervation by targeting deep tissue radiofrequency ablation in the area where the bronchial and vagus nerve is enriched, thereby reducing the air in the entire lung.
Obstruction of the tract, to achieve the role of treatment of chronic obstructive pulmonary disease
.
Compared with the same type of products currently developed, Kunbo Medical’s TLD is simple to operate and short in operation time (approximately 10-20 minutes), and adopts small catheter ablation and intelligent infusion of cold saline to improve the effectiveness of treatment and ensure the safety of surgery
Professor Luo Fengming from West China Hospital said after surgery: “There is no effective surgical treatment for COPD patients, and the effects of medical drugs are also very limited.
To provide a solution, the unique design of the TLD jointly developed by West China Hospital and Kunbo Medical will improve the effectiveness while ensuring the safety of ablation.
We look forward to the rapid clinical application of this technology
.
"
The successful first clinical application of Kunbo Medical's lung targeted denervation radiofrequency ablation energy system shows that in addition to the InterVapor hot steam energy ablation system, Kunbo Medical has achieved breakthroughs in another major product in the treatment of chronic obstructive pulmonary and asthma.
Progress
.
In the future, Kunbo Medical will continue to innovate and develop more "toolboxes" of treatment solutions for unsatisfied lung diseases based on its unique navigation system
About Kunbo Medical
Kunbo Medical, a pioneer in the field of interventional respiratory medicine, provides innovative lung disease solutions in China and globally
.
Since its establishment in 2012, Kunbo Medical has assembled a management team with extensive experience in product development, clinical research and commercialization, and has developed into an enterprise with a China-US dual center
Kunbo Medical's vision is to become a global leader in the transformation of lung disease treatment, and to establish Kunbo's interventional diagnosis and treatment solutions as the gold standard for lung disease treatment
Source: Kunbo Medical
